Back to Newsroom

Understanding Breast Cancer Screening Guidelines: What Every Provider Should Know

Tanya Gupta, M.D.

Medical Director

A signpost with five arrows asking: Start at 40? Annually or every 2 years? Add ultrasound? Add MRI? Is it recommended or not?

Breast cancer screening is a cornerstone of preventive healthcare, yet determining the right screening approach for each patient is not always straightforward.

Leading medical organizations agree that mammography plays a critical role in early breast cancer detection. However, their recommendations differ regarding when screening should begin, how frequently it should occur, and when supplemental imaging may be appropriate.

For physicians, understanding these differences is essential to helping patients make informed decisions—particularly those with dense breast tissue, elevated breast cancer risk, or questions following mammography.

How Do Breast Cancer Screening Guidelines Compare?

The U.S. Preventive Services Task Force (USPSTF), National Comprehensive Cancer Network (NCCN), American College of Radiology (ACR), American College of Obstetricians and Gynecologists (ACOG), and American Cancer Society (ACS) provide guidance on breast cancer screening.

While all recognize the importance of mammography, their approaches reflect different interpretations of screening benefits, potential harms, and individual risk.

OrganizationStarting Age for Average-Risk WomenScreening Frequency
USPSTF (2024)140Every 2 years through age 74
NCCN240Annually
ACR/SBI340Annually
ACOG (2024)440Every 1–2 years
ACS540–44 optional; 45 recommendedAnnually ages 45–54; every 2 years or annually beginning at 55

Recommendations summarized for average-risk, asymptomatic women. Screening beyond age 74–75 depends on the organization, health status, life expectancy, and patient preferences.

The most significant differences involve screening frequency and the degree to which individual risk influences recommendations.

The USPSTF favors biennial screening based on its assessment of benefits and potential harms. In contrast, NCCN and ACR recommend annual screening beginning at age 40, emphasizing opportunities for earlier detection.

ACOG supports shared decision-making regarding annual versus biennial screening, while ACS provides age-specific recommendations.

The clinical takeaway: Guidelines establish a foundation for care, but individualized screening decisions remain essential.

How Does Breast Density Affect Screening Recommendations?

Breast density presents an important challenge in breast cancer screening.

Approximately half of women undergoing mammography have dense breasts, according to the National Cancer Institute.6 Dense breast tissue creates two distinct concerns:

  • Reduced mammographic sensitivity: Dense fibroglandular tissue can obscure malignancies because both dense tissue and tumors appear white on mammograms.

  • Increased breast cancer risk: Breast density is independently associated with increased breast cancer risk.

These factors can complicate screening decisions even when mammography results are negative.

Guidelines differ in their approach to supplemental screening.

The USPSTF concludes that evidence is insufficient to determine the balance of benefits and harms of supplemental ultrasound or MRI following a negative mammogram in women with dense breasts.

ACR guidance is more supportive of supplemental imaging, particularly MRI, depending on breast density and overall risk.

NCCN recommends considering supplemental screening for women with heterogeneously or extremely dense breasts.

Importantly, an insufficient-evidence determination does not mean supplemental screening is ineffective. Rather, it reflects uncertainty about its overall benefits and harms across the population being evaluated.

For physicians, breast density should prompt a broader conversation about individual risk and whether additional screening may provide meaningful clinical value.

When Does Breast Cancer Risk Change Screening Recommendations?

Women at elevated risk may benefit from screening strategies that begin earlier or incorporate additional imaging.

Factors that can influence risk include:

  • Pathogenic variants in breast cancer susceptibility genes, including BRCA1 and BRCA2

  • Strong family history of breast or ovarian cancer

  • Prior therapeutic chest radiation at a young age

  • Certain high-risk breast lesions

  • Elevated lifetime risk calculated using validated assessment models

  • Personal history of breast cancer

For many women with a calculated lifetime breast cancer risk of 20% or greater, professional guidelines recommend annual breast MRI in addition to mammography.

ACR also emphasizes risk assessment by age 25 to identify individuals who may benefit from earlier or more intensive screening.

Importantly, breast density and elevated lifetime risk are not interchangeable. A patient with dense breasts may be at average, intermediate, or high overall risk.

A comprehensive risk assessment helps physicians determine whether standard mammography is sufficient or whether additional screening should be considered.

Why Can Screening Guidelines Be Challenging to Apply in Clinical Practice?

Even with established recommendations, physicians must navigate several practical challenges.

1. Different recommendations can create uncertainty

Patients may receive conflicting advice about annual versus biennial screening, especially when recommendations differ between primary care, radiology, and specialty providers.

2. A negative mammogram does not eliminate risk

Mammography remains the foundation of screening, but its limitations are particularly relevant for women with dense breasts.

3. Supplemental imaging introduces trade-offs

MRI and ultrasound may identify additional cancers but can also increase false-positive findings, recalls, costs, and unnecessary procedures.

4. Access and adherence can be barriers

Insurance coverage, scheduling availability, geographic access, and patient preferences can influence whether recommended screening is completed.

These challenges reinforce the importance of shared decision-making and clear follow-up pathways.

How Can Physicians Guide Patients Through Screening Decisions?

A practical, patient-centered approach can help translate screening guidelines into individualized care.

Assess risk early and reassess periodically. Review personal and family history, prior biopsies, breast density, and relevant genetic risk factors. Use validated risk assessment tools when appropriate.

Explain the role and limitations of mammography. Reinforce that mammography remains essential while acknowledging that additional screening may be appropriate for certain patients.

Discuss supplemental options. Depending on risk, breast density, and clinical circumstances, options may include breast MRI, ultrasound, or contrast-enhanced mammography.

Clarify benefits and trade-offs. Discuss additional cancer detection, false positives, follow-up procedures, patient preferences, and financial considerations.

Establish a clear follow-up plan. Ensure that abnormal findings receive timely diagnostic evaluation and that patients understand their recommended screening schedule.

A thoughtful screening conversation does more than explain guidelines. It helps patients understand why a particular approach is appropriate for them.

Where Do Emerging Blood-Based Tests Fit Into Breast Cancer Screening?

As breast cancer screening evolves, researchers are investigating blood-based technologies that may provide additional biological information alongside imaging.

One example is Certitude®, a blood-based breast cancer test developed by Astrin Biosciences for women with dense breasts.

Certitude uses deep proteomic analysis and machine learning to identify blood-based patterns associated with breast cancer.

Clinical research has demonstrated approximately 93% sensitivity and a negative predictive value exceeding 99% in studied populations, supporting its potential as an additional source of information in breast cancer detection.7

Certitude is a laboratory-developed test performed in a CLIA-certified, CAP-accredited laboratory.

Certitude is not currently included in major breast cancer screening guidelines and is not intended to replace mammography, recommended supplemental imaging, or indicated diagnostic evaluation. A negative result does not exclude cancer in every patient, and suspicious imaging findings still require appropriate follow-up.

For physicians managing patients with dense breasts, emerging blood-based approaches may offer another layer of insight as the evidence base continues to develop.

The Future of Breast Cancer Screening Is More Personalized

Breast cancer screening guidelines provide an essential foundation, but no single approach addresses every patient's needs.

The opportunity for physicians is to combine evidence-based recommendations with individualized risk assessment, patient preferences, and emerging scientific advances.

For women with dense breasts, this means looking beyond screening frequency alone and considering how different technologies may complement established care.

By understanding where guidelines agree, where they differ, and where innovation may contribute, physicians can help patients make informed decisions about their breast health.

Explore the clinical evidence behind Certitude and learn how this blood-based test may complement breast cancer screening for your patients.

Learn More About Certitude for Healthcare Providers

Footnotes

  1. Recommendation: Breast Cancer: Screening | United States Preventive Services Taskforce ↩

  2. NCCN Guidelines for Patients: Breast Cancer Screening and Diagnosis ↩

  3. ACR Appropriateness Criteria® Female Breast Cancer Screening: 2025 Update - Journal of the American College of Radiology ↩

  4. Breast Cancer Risk Assessment and Screening in Average-Risk Women | ACOG - College ↩

  5. ACS Breast Cancer Screening Guidelines | American Cancer Society ↩

  6. Dense Breasts: Answers to Commonly Asked Questions - NCI ↩

  7. Development and Validation of a Machine-Learning Deep Plasma Proteome | BCTT | Dove Medical Press ↩

Certitude

1000 Westgate Drive
St. Paul, MN 55114

© Astrin Biosciences 2025. All rights reserved.

The Certitude Test is a laboratory developed test (LDT) from Astrin Biosciences Inc., and is performed by Clinical Laboratory Improvement Amendments (CLIA) certified, College of American Pathologists (CAP) accredited laboratories qualified to conduct high-complexity clinical testing and is only intended for use consistent with applicable CLIA and CAP requirements. The Certitude test performance characteristics were validated by Astrin Biosciences following CAP and CLIA regulations. When offered as an LDT, the Certitude Test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).